In this study, we discovered that the tumor-infiltrating M-MDSCs overexpress 6-phosphogluconate dehydrogenase (6PGD), a rate-limiting enzyme in the pentose phosphate pathway (PPP), which plays a key role in regulating M-MDSC metabolic reprogramming, their suppressive functions and subsequent tumor outcomes. The gene discussed is PGD; the disease is neoplasm.